Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ZTlido (Lidocaine Topical System) 1.8%, ZTlido 1.8%
ZTlido · 1 trial · 1 indication
The adhesion performance (i.e., degree of lifting or detachment) is assessed by clinicians at each time point. The adhesion of Test Products 1, 2, and 3 (each over-the-counter external analgesic lidocaine-containing patch) are compared to the adhesion performance observed for the Reference Product.
| Arm | Type | Description |
|---|---|---|
| ZTlido (Lidocaine Topical System) 1.8% | OTHER | - |
| Salonpas (Lidocaine Patch 4%) | OTHER | - |
| Aspercreme (Lidocaine Patch 4%) | OTHER | - |
| IcyHot (Lidocaine 4% + Menthol 1% Patch) | OTHER | - |
| Name | Type | Description |
|---|---|---|
| ZTlido (Lidocaine Topical System) 1.8% | DRUG | 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours |
| Salonpas (Lidocaine Patch 4%) | DRUG | 1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours |
| Aspercreme (Lidocaine Patch 4%) | DRUG | 1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours |
| IcyHot (Lidocaine 4% + Menthol 1% Patch) | DRUG | 1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours |
Inclusion Criteria: * Healthy, male and female subjects aged 18 years and older with a Body Mass Index (BMI) range 18.0-32.49 kg/m2 inclusive (according to the formula of BMI = weight (kg) / \[height (m)2\]). * Subjects who have no evidence of underlying disease during screening and check-in and wh...
ZTlido 1.8% is a small molecule drug being developed by Scilex Holding Company (SCLX). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied for its adhesive properties compared to other lidocaine-containing patches.
ZTlido 1.8% is a lidocaine-containing patch. Lidocaine is a local anesthetic that works by blocking nerve signals in the body. The drug is being studied for its adhesion characteristics in a clinical trial involving healthy volunteers.
ZTlido 1.8% is being developed by Scilex Holding Company, which trades under the ticker symbol SCLX. The company is conducting clinical research on this drug for use in healthy volunteers.
ZTlido 1.8% is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, with no active trials currently ongoing.
ZTlido 1.8% has one completed clinical trial, NCT05106400, titled 'Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches'. This Phase 1 study enrolled 24 healthy volunteers in the United States.
ZTlido 1.8% is being studied in comparison to three over-the-counter external analgesic lidocaine-containing patches. The clinical trial NCT05106400 was designed to assess the adhesion properties of ZTlido 1.8% relative to these other products.